How Much Upside Is Left in Exscientia (EXAI)? Wall Street Analysts Think 61.43%

Yahoo FinanceJun 19 09:55 ET

Morgan Stanley Maintains Exscientia(EXAI.US) With Hold Rating, Maintains Target Price $7

Morgan Stanley analyst Vikram Purohit maintains $Exscientia(EXAI.US)$ with a hold rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success rate of 0.0% and a

moomoo NewsJun 17 08:33 ET · Ratings

Painful Week for Individual Investors Invested in Exscientia Plc (NASDAQ:EXAI) After 12% Drop, Institutions Also Suffered Losses

Key Insights The considerable ownership by individual investors in Exscientia indicates that they collectively have a greater say in management and business strategy A total of 6 investors have a ma

Simply Wall StJun 11 09:50 ET

Germany's Merck Bets on AI Drug-Design Partnerships, Rules Out Acquisitions - Interview

By Helena Smolak and Stefanie Haxel Germany's Merck KGaA is betting on artificial-intelligence partnerships to develop new drugs, but refraining from bringing in external expertise through acquisitio

WSJJun 7 07:55 ET

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

— AI drug design pioneer John P. Overington, Ph.D., appointed to Chief Technology Officer to maximise strategic technology integration and application — — Maria-Louise Fjällskog, M.D., Ph.D., appointed interim Chief

BusinesswireJun 6 07:00 ET

Can Exscientia (EXAI) Climb 57.17% to Reach the Level Wall Street Analysts Expect?

Yahoo FinanceJun 3 09:55 ET